Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

On April 8, the FDA approved use of this drug combination for adults and children age 12 and older whose colorectal cancer ... Opdivo alone or chemotherapy. Results showed the immunotherapy ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...

Dr. Changxing Liu with Ascension St. John Medical Center outlines how Oklahomans can lower their risk of head and neck cancer ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

Secondary endpoints backed up the main findings, including a 68% objective response rate with Keytruda/Padcev versus ... cancer patients, who face an urgent need for new therapies.” Chemo ...

Oncology Clinical Trials Market has been steadily growing over the years due to increasing incidence of cancer, advancements ...

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

Chimeric antigen receptor (CAR-T) cell therapy is a rapidly growing frontier in cancer research, with Australian biotech ...

The approval was based on the KEYNOTE-966 study, which found a statistically significant and clinically meaningful improvement in overall survival (OS) versus chemo alone in newly diagnosed BTC ...

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.